Syntis Bio

Boston, United States

Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases.

$33.0M raised

Jul 2025

Series A

Health Care Medical Therapeutics

Top Investors

Safar PartnersCerity Partners VenturesCerberus Capital ManagementNational Institutes of HealthBold Capital Partners

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Syntis Bio

How much funding has Syntis Bio raised?

Syntis Bio has raised $33.0M in total funding. The most recent round was Series A. The last funding was announced in July 2025.

Who are Syntis Bio's investors?

Syntis Bio's investors include Safar Partners, Cerity Partners Ventures, Cerberus Capital Management, National Institutes of Health, Bold Capital Partners.

Where is Syntis Bio headquartered?

Syntis Bio is headquartered in Boston, United States.

What does Syntis Bio do?

Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases.

What stage is Syntis Bio at?

Syntis Bio is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 1, 2025.

MLA

"Syntis Bio — Funding & Investors." VCBacked, July 1, 2025, https://www.vcbacked.co/company/syntis-bio. Accessed June 3, 2026.

APA

VCBacked. (2025). Syntis Bio — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/syntis-bio

Wikipedia (cite web)

{{cite web |title=Syntis Bio — Funding & Investors |url=https://www.vcbacked.co/company/syntis-bio |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 1, 2025.

Similar Companies in Health Care